The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • NeuroScientific Biopharmaceuticals (NSB) recruits its first subject for an early-phase clinical trial
  • The clinical stage drug development company announced the recruitment for its trial for lead drug candidate, EmtinB to treat neurodegenerative conditions, such as multiple sclerosis and Alzheimer’s disease
  • The clinical trial is being undertaken by WA-based clinical research partner, Linear Clinical Research, and will see up to 30 healthy volunteers undergo treatment
  • This will then be used to guide efficacy outcomes during future trials  
  • NeuroScientific Biopharmaceuticals is in the grey, trading at 17.5 cents at 12:36 pm AEST

NeuroScientific Biopharmaceuticals (NSB) has recruited its first subject for its early-phase clinical trial.

The clinical stage drug development company announced the recruitment for its trial for lead drug candidate, EmtinB.

The drug is hoped to be a first-in-class treatment with disease modifying potential for neurodegenerative conditions, such as multiple sclerosis and Alzheimer’s disease.

EmtinB has been modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.

The clinical trial is being undertaken by WA-based clinical research partner, Linear Clinical Research, and will see up to 30 healthy volunteers undergo treatment.

The study will involve the assessment of biomarkers in human blood samples that indicate proof of the mechanism of activity of EmtinB in humans.

This can then be used to guide efficacy outcomes during future trials.

NeuroScientific’s Managing Director and Chief Executive Officer Matt Liddelow said the news marks another historic achievement for the company.

Matt Liddelow described the news as “a major milestone in developing EmtinB as a much-needed therapeutic treatment with disease modifying potential for patients with Multiple sclerosis and Alzheimer’s disease.”

NeuroScientific Biopharmaceuticals were in the grey, trading at 17.5 cents at 12:36 pm AEST.

NSB by the numbers
More From The Market Online
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…